Eteplirsen approved for Duchenne muscular dystrophy

被引：6
|
作者：
Traynor, Kate
机构：
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2016年 / 73卷 / 21期
关键词：
D O I：
10.2146/news160063
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1719 / 1719
页数：1
相关论文
共 50 条
  • [31] FDA Approval of Eteplirsen for Muscular Dystrophy
    Nelson, Stanley F.
    Miceli, M. Carrie
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (14): : 1480 - 1480
  • [32] UPDATE ON THE ETEPLIRSEN MUSCULAR DYSTROPHY PROGRAM
    Mendell, J. R.
    Rodino-Klapac, L.
    Sahenk, Z.
    Roush, K.
    Bird, L.
    Lowes, L. P.
    Alfano, L.
    Gomez, A. M.
    Lewis, S.
    Malik, V.
    Shontz, K.
    Flanigan, K. M.
    Shilling, C.
    Sazani, P.
    Saoud, J.
    Duda, P.
    Kaye, E. M.
    [J]. MUSCLE & NERVE, 2014, 50 : S1 - S1
  • [33] Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case
    Dal-Re, Rafael
    Lopez de Munain, Adolfo
    Ayuso, Carmen
    [J]. REVISTA DE NEUROLOGIA, 2017, 65 (08) : 373 - 380
  • [34] Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt
    Shehata, Zahraa
    Metry, Andrew
    Rabea, Hoda
    El Sherif, Rasha
    Abdelrahim, Mohamed
    Dawoud, Dalia
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 38 : 109 - 117
  • [35] Eteplirsen, a Phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): Clinical update
    Kaye, E.
    Mendell, J.
    Rodino-Klapac, L.
    Sahenk, Z.
    Lowes, L.
    Alfano, L.
    Berry, K.
    Ramirez, A. Gomez
    Lewis, S.
    Flanigan, K.
    Cripe, L.
    Al-Zaidy, S.
    Duda, P.
    Sazani, P.
    Saoud, J.
    [J]. NEUROMUSCULAR DISORDERS, 2015, 25 : S263 - S263
  • [36] Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
    Iff, Joel
    Zhong, Yi
    Tuttle, Edward
    Gupta, Deepshekhar
    Paul, Xander
    Henricson, Erik
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (09)
  • [37] FDA Approval of Eteplirsen for Muscular Dystrophy Reply
    Kesselheim, Aaron S.
    Avorn, Jerry
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (14): : 1481 - 1482
  • [38] Respiratory function in eteplirsen-treated Duchenne muscular dystrophy (DMD) patients compared to natural history
    Kinane, B.
    Mayer, O.
    Lowes, L.
    Khan, N.
    Gallitano, K.
    Duda, P.
    Mendell, J.
    [J]. NEUROMUSCULAR DISORDERS, 2016, 26 : S154 - S154
  • [39] Delay in Duchenne Muscular Dystrophy Progression with Eteplirsen: Longer Time to Loss of Ambulation Versus Standard of Care
    Iff, J.
    Bungey, G.
    Paine, A.
    Han, B.
    Gordish-Dressman, H.
    Henricson, E.
    McDonald, C.
    [J]. ANNALS OF NEUROLOGY, 2021, 90 : S152 - S152
  • [40] Duchenne muscular dystrophy
    Yiu, Eppie M.
    Kornberg, Andrew J.
    [J]. NEUROLOGY INDIA, 2008, 56 (03) : 236 - 247
12345